Premium
Clinical Study on the Low‐Dose Norgestrel Ethinyl Estradiol Combination as An oral Contraceptive.
Author(s) -
Higashiyama Shusei,
Iwasaki Takeki,
Kizu Shuji,
Okada RHiroji
Publication year - 1976
Publication title -
the journal of the asian federation of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0377-0532
DOI - 10.1111/j.1447-0756.1976.tb00337.x
Subject(s) - norgestrel , medicine , amenorrhea , metrorrhagia , breakthrough bleeding , mestranol , pregnancy , liver function , menstruation , gynecology , menstrual cycle , weight gain , population , levonorgestrel , family planning , gastroenterology , body weight , hormone , research methodology , environmental health , biology , genetics
A low dose of oral contraceptive, containing 0.5 mg norgestrel and 0.05 mg ethinyl estradiol, was given daily tc 303 women for a total of 5,159 cycles in order to study its efficacy and acceptability as an oral contraceptive agent. Only one pregnancy occurred. The cycle length was markedly stabilized, and the duration of bleeding was shortened and 88.5% of the treated cycles were 3 to 5 davs. Breadthrough bleeding and amenorrhea occurred rarely during the cycles under medication. Main side effects observed were gastro‐intestinal symptoms and weight gain. The gastro‐intestinal symptoms were more frequent in the first 3 cycles, but gradually decreased in later cycles, showing good tolerance of the drug, while the weight gain occurred in 4.2% of 303 women. In the liver function tests employed, abnormalities in BSP retention, serum transaminase values or TTT were recorded in a limited number of cases. However, neither jaundice nor thrombophlebitis was observed in any cases treated, while hypertension occurred in 4 cases. The drug investigated can be evaluated as acceptable to most women seeking contraception .